Allspring Global Investments Holdings LLC Sells 67,795 Shares of United Therapeutics Corporation $UTHR

Allspring Global Investments Holdings LLC cut its stake in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 70.1% in the third quarter, Holdings Channel reports. The institutional investor owned 28,901 shares of the biotechnology company’s stock after selling 67,795 shares during the period. Allspring Global Investments Holdings LLC’s holdings in United Therapeutics were worth $16,513,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Hohimer Wealth Management LLC acquired a new position in United Therapeutics during the third quarter worth $6,819,000. University of Texas Texas AM Investment Management Co. increased its holdings in United Therapeutics by 53.1% during the 3rd quarter. University of Texas Texas AM Investment Management Co. now owns 14,282 shares of the biotechnology company’s stock worth $7,739,000 after purchasing an additional 4,954 shares during the period. Candriam S.C.A. raised its position in United Therapeutics by 2.7% in the 3rd quarter. Candriam S.C.A. now owns 55,109 shares of the biotechnology company’s stock valued at $29,972,000 after purchasing an additional 1,425 shares in the last quarter. Ethic Inc. boosted its stake in shares of United Therapeutics by 60.0% in the 3rd quarter. Ethic Inc. now owns 2,463 shares of the biotechnology company’s stock valued at $1,335,000 after buying an additional 924 shares during the period. Finally, StoneX Group Inc. purchased a new stake in shares of United Therapeutics in the 3rd quarter valued at approximately $400,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at United Therapeutics

In related news, CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $593.99, for a total value of $5,642,905.00. Following the completion of the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $192,715,897.57. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christopher Patusky sold 1,210 shares of the stock in a transaction on Monday, November 9th. The shares were sold at an average price of $580.00, for a total transaction of $701,800.00. Following the transaction, the director owned 2,140 shares in the company, valued at $1,241,200. This trade represents a 36.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 412,238 shares of company stock valued at $220,975,006. 8.60% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Down 0.4%

NASDAQ UTHR opened at $591.17 on Friday. United Therapeutics Corporation has a fifty-two week low of $455.63 and a fifty-two week high of $614.23. The business has a fifty day moving average of $542.60 and a 200-day moving average of $536.37. The stock has a market cap of $25.18 billion, a price-to-earnings ratio of 22.31, a price-to-earnings-growth ratio of 3.94 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The firm had revenue of $832.50 million during the quarter, compared to analysts’ expectations of $781.14 million. During the same period in the previous year, the company earned $7.16 earnings per share. The business’s quarterly revenue was up 4.1% on a year-over-year basis. As a group, analysts anticipate that United Therapeutics Corporation will post 25.08 EPS for the current year.

United Therapeutics declared that its Board of Directors has approved a stock repurchase program on Thursday, October 22nd that permits the company to repurchase $2 billion in outstanding shares. This repurchase authorization permits the biotechnology company to buy up to 8.3% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on UTHR shares. TD Cowen lifted their price objective on shares of United Therapeutics from $675.00 to $700.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. BTIG Research increased their target price on United Therapeutics from $728.00 to $768.00 and gave the company a “buy” rating in a report on Wednesday, November 4th. Weiss Ratings cut United Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday. UBS Group set a $725.00 price target on United Therapeutics in a report on Monday, October 19th. Finally, JPMorgan Chase & Co. lowered their price objective on United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a research report on Wednesday, October 28th. Twelve investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $676.40.

Check Out Our Latest Stock Report on UTHR

About United Therapeutics

(Free Report)

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.

Featured Stories

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.